HOME >> MEDICINE >> NEWS
St. Jude leukemia therapy overcomes differences in treatment outcome between black, white children

(MEMPHIS, TENN.--October 14, 2003) Investigators at St. Jude Children's Research Hospital have found that black children are equally likely as white children to benefit from improved treatment for acute lymphoblastic leukemia (ALL), if given equal access to the most advanced therapies.

This finding--that black and white children had virtually equal rates of survival over 10 years--contrasts with the results of clinical studies from the Pediatric Oncology Group (POG) and Children's Cancer Group (CCG). The POG and CCG multi-center studies showed that black children lagged behind white children in the cure rate for ALL.

Even though black children referred to St. Jude were more likely to have high-risk leukemia and be socioeconomically underprivileged, they enjoyed the same excellent treatment results as white children, according to Ching-Hon Pui, M.D., director of the St. Jude Leukemia/Lymphoma division.

Pui is senior author of this study, which appears in the Oct. 15 issue of the Journal of the American Medical Association. Despite black children presenting with more bulky disease at diagnosis and having unfavorable genetic subtypes of leukemia, the St. Jude treatment was able to achieve high cure rates that were equal in black and white children.

"It's remarkable that, although African-American children with ALL are more likely than white children to have high-risk leukemia, the black children in our studies derived as much benefit from therapy as white children," said William Evans, Pharm.D., St. Jude scientific director and a co-author of the study. "This is apparently due to the modifications we made to our previous, very successful therapies for ALL, making those treatments even more effective."

One factor contributing to the treatment success rate among black children is that all St. Jude patients received a personally tailored approached to treatment--called risk-directed therapy--regardless of health insurance s
'"/>

Contact: Bonnie Cameron
bonnie.cameron@stjude.org
901-495-4815
St. Jude Children's Research Hospital
14-Oct-2003


Page: 1 2

Related medicine news :

1. Both inherited traits and tumor mutations affect response to treatment of leukemia
2. Plant derivative attacks the roots of leukemia
3. Protein that promotes survival of stem cells might be key to poor leukemia prognosis
4. Study finds new designer drug is potent treatment for chronic myelogenous leukemia
5. Study finds new designer drug is potent treatment for chronic myelogenous leukemia
6. New leukemia drug shows promise in overriding all Gleevec resistance
7. Cord blood transplantation now a viable option for adult leukemia patients
8. Peptide vaccine can produce complete remission in myeloid leukemia patients
9. Methylphenidate improves attention, behavior of children surviving leukemia, brain tumors
10. Obesity linked to another cancer - leukemia in older women
11. Improved acute lymphoblastic leukemia treatment offers hope for eliminating irradiation

Post Your Comments:
(Date:11/27/2014)... Cambrionix Ltd today announced that it ranked number ... of the 50 fastest-growing technology companies in the UK. ... five years. Cambrionix Ltd grew 2989 percent during this ... region of Cambridgeshire and East and first in the sector ... is recognition of the hard work put in by our ...
(Date:11/27/2014)... PITTSBURGH, PA (PRWEB) November 27, 2014 ... suffer from an embarrassing fact of life, and she ... musty a few minutes later, I decided that there ... longer periods," she said. , Easy to use and ... maintains freshness in a woman’s private areas throughout the ...
(Date:11/27/2014)... Dotinga HealthDay Reporter , WEDNESDAY, ... pre-wired to acquire a second language, new research suggests. But ... likely gain a brain boost, the small study finds. ... said study co-author Ping Li, co-director of the Center for ... even more interesting, Li said, that "the brain networks of ...
(Date:11/27/2014)... THURSDAY, Nov. 27, 2014 (HealthDay News) -- Thanksgiving meals ... eat a gluten-free diet, an expert says. Many ... potatoes and cranberry sauce -- are gluten-free, but "when ... may need to be considered," Dr. Anca Safta, director ... Wake Forest Baptist Medical Center in North Carolina, said ...
(Date:11/27/2014)... NC (PRWEB) November 27, 2014 ... 12 years in the Charlotte area providing audits, ... examination services to businesses of varying size across ... business owners to meet all of their accounting ... certification through the QuickBooks ProAdvisor Program. When asking ...
Breaking Medicine News(10 mins):Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 2Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 3Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 4Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Expert Shares Gluten-Free Thanksgiving Tips 2Health News:Jeffrey Carlini becomes Intuit Proadvisor and receives QuickBooks certification 2
(Date:11/26/2014)... Zynerba Pharmaceuticals , Inc., a specialty ... synthetic cannabinoid treatments, today announced that the company will ... 2014. The conference will be held December 2 to ... New York . Zynerba,s Chairman and CEO, ... Tuesday, December 2. To listen to a ...
(Date:11/26/2014)... JOSE, Calif. , Nov. 26, 2014 /PRNewswire/ ... technologies to produce novel therapies for infectious diseases, ... , M.D., an internationally recognized key opinion leader ... the Company,s scientific advisory board. Founder ... Ph.D., stated, "We believe Dr. Opal,s extensive experience ...
(Date:11/26/2014)... NEW YORK and ... the leading distributor of market intelligence, MarketResearch.com is pleased ... by IQ4I Research and Consultancy focusing on the active ... about IQ4I Research visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . ... Ingredients Global Market – Forecast to 2020 ...
Breaking Medicine Technology:Zynerba Pharmaceuticals to Present at Piper Jaffray 26th Annual Healthcare Conference 2014 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3
Cached News: